Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence
NCT04704050 · Tulane University School of Medicine · PHASE4 · terminated · last registry update 2025-10-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor withdrew funding” | – | Registry record, Tulane University School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CACNA1C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-27Also stopped (suspended): University of California, Irvine, Nortriptyline + Topiramate (NCT06799169)
- 2026-10-19Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release + blood sampling (NCT07880769)
- 2026-09-24Also stopped (terminated): HB BioTech, LLC, HB-1 + Telmisartan Only Product in Oral Dose Form (NCT06483789)
- 2026-09-21Results posted on the registry: Barts & The London NHS Trust, Medical treatment alone (NCT01411371)
- 2026-09-10Also stopped (terminated): CAMC Health System, Metoprolol + Diltiazem (NCT02025465)
- 2026-09-04Phase 3 first posted: Ain Shams University, Verapamil oral + Placebo (NCT07804849)
- 2026-06-01Phase 3 first posted: Zentiva, k.s., Amlodipine (NCT07618806)
- 2026-04-16Results posted on the registry: University of California, Irvine, Nortriptyline + Topiramate + Verapamil + Paroxetine (NCT04404439)
- 2025-12-24Phase 3 first posted: University Hospital, Basel, Switzerland, DEB-DoxNic-TACE + current standard of care (NCT07302919)
- 2025-11-10Results posted on the registry: Wake Forest University Health Sciences, Calcium pre-treatment (NCT05661942)
- 2025-10-14Results posted on the registry: Vanderbilt University Medical Center, diltiazem (NCT06534671)
- 2025-10-10Results posted on the registry: Mersin Medicalpark Hastanesi, Verapamil (NCT06447688)
- 2025-09-22Also stopped (terminated): Viatris Innovation GmbH, ACT-334441 2 mg + ACT-334441 4 mg (NCT02479204)
- 2025-05-11Results posted on the registry: Peng Roc Chen, MD, Nicardipine + Verapamil (NCT01996436)
- 2025-05-11Also stopped (terminated): Peng Roc Chen, MD, Nicardipine + Verapamil (NCT01996436)
- 2025-02-25Results posted on the registry: Stanford University, Nebivolol + Diltiazem (NCT04130438)
- 2025-02-25Also stopped (terminated): Stanford University, Nebivolol + Diltiazem (NCT04130438)
- 2025-02-06Results posted on the registry: Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-02-06Also stopped (terminated): Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-01-13Phase 3 first posted: CSPC ZhongQi Pharmaceutical Technology Co., Ltd., SYH9056 + Levamlodipine (NCT06771245)
- 2024-12-27Results posted on the registry: Corewell Health South, Oral + Intravenous drug (NCT05391893)
- 2024-12-05Phase 3 first posted: Rashid Latif Medical College, Adenosine + Verapamil Injection (NCT06717685)
- 2024-11-27Results posted on the registry: Jaeb Center for Health Research, verapamil 120mg tablet + placebo (NCT04233034)
- 2024-11-07Phase 3 first posted: Yonsei University, BP lowering drugs (nicardipine, labetalol, urapidil) + BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil) (NCT06677970)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision